A treatment for activated B-cell-like DLBCL?
Mené sur 32 patients atteints d'un lymphome diffus à grandes cellules B CD20+, cet essai franco-américain de phase 1b évalue la dose maximale tolérée et l'activité antitumorale de l'ibrutinib, en combinaison avec un protocole R-CHOP, pour un traitement de première ligne
Diffuse large B-cell lymphoma (DLBCL) outcomes have improved in the past decade and novel drug therapies will probably lead to further improvements. At present, clinical prognostic factors have limited ability to identify any patient subset with sufficiently poor responses to justify deviating from R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) outside of a clinical trial. DLBCL is a heterogeneous disease in terms of clinical presentation and pathological and mole ...
The Lancet Oncology , commentaire, 2013